LUCD

LUCD

Lucid Diagnostics Inc

Net -27.41%top 1%Rev 8.28%top 1%Revenue grew 100% of years1Y
Hold

Lucid Diagnostics Inc. develops medical diagnostic solutions that focus on early detection of esophageal precancer in patients with gastroesophageal reflux disease (GERD) through its EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$987today

Score Overview

1 Year
Scoreโ€”
Net Growth-27.41%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth8.28%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-106.60%
Net Trend50%
Net Income Consistency
Rev Growth9x
Rev Trend75%
Revenue Consistency

See the full market ranking โ†’

Lucid Diagnostics Inc fundamental performance

Across Lucid Diagnostics Inc's full reported history, from 2021 to 2025, revenue grew from $ 500K to $ 4M and net income went from -$ 28M to -$ 58M. Revenue increased in 75% of the years measured; net income in 50%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.98โ€”
1 Year2025-08-12
$ 1.00-1.31%
All Time2021-10-14
$ 11.76-91.63%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2025$ 4M-$ 58M$ 34.70B
2024$ 4M-$ 45M$ 22M
2023$ 2M-$ 52M$ 18M
2022$ 377K-$ 56M$ 22M
IPO2021$ 500K-$ 28M$ 53M

Explore beyond LUCD

You're looking at Lucid Diagnostics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies